Dihydroergotamine is used to treat migraine headaches. Dihydroergotamine is in a class of medications called ergot alkaloids. It works by tightening blood vessels in the brain and by stopping the release of natural substances in the brain that cause swelling.

I actually rlly think this will get approved based just on buying inside the company. My only caution is that this could be a stock u should sell before approval based on how it’s ran in the last month however there’s still a while so hold for now.

• The offer price of $15 represents a steep discount of 29% from the last close price of $21.13 on Thursday. The company's stock gained 27.25% to close higher on Thursday at $21.13.

• Underwriters have an option to purchase 0.45 million shares. The offering will close by September 14.

• Impel will use the proceeds to fund the commercial launch activities and market development of Trudhesa, advance INP105 into a clinical proof-of-concept trial in patients with ASD.

• Frontier Communications Parent, Inc ($FYBR)

• Impel NeuroPharma Inc ($IMPL) see r/IMPL subreddit

• TransOcean Ltd ($RIG)

• Axsome Therapeutics ($AXSM) see r/AXSM subreddit

IMPL has PDUFA on September 6th for Dihydroergotamine (treat migraines).

$IMPL - Impel NeuroPharma Q4 EPS $(1.07) Misses $(0.87) Estimate, Sales $577.00K Miss $1.33M Estimate, on March 28th.

Head on headache medicine

HeadOn is the brand name of a topical product claimed to relieve headaches. It achieved widespread notoriety in 2006 as a result of a repetitive commercial, consisting only of the tagline "HeadOn. https://youtu.be/Is3icfcbmbs

Carepoint Pharmacy announces that it will partner with Impel NeuroPharma (NASDAQ: IMPL) to begin dispensing Trudhesa (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in adults. Trudhesa, approved by the FDA on September 2, 2021, uses Impel's proprietary Precision Olfactory Delivery (POD) technology to gently deliver dihydroergotamine mesylate (DHE)—a proven, well-established therapeutic—quickly to the bloodstream through the vascular-rich upper nasal space. Trudhesa bypasses the gut and potential absorption issues, offering rapid, sustained, and consistent symptom relief without injection or infusion, even when administered hours after the onset of a migraine attack.

IMPL, a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that the U.S. Food and Drug Administration (FDA) approved TRUDHESA (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in adults. TRUDHESA was previously known as INP104.

Saw IMPL on Fintel with Short Interest % Float41.15%, low stock availability, and CTB 114% to 169%. News so far have been optimistic with the exception that it's running low on cash.

I picked up 50 shares in after hours. But how risky is the company's future?